Go Pro
NASDAQ:CYPH

Cypherpunk Technologies Q2 2024 Earnings Report

Cypherpunk Technologies logo
$0.67 +0.02 (+3.40%)
As of 04:00 PM Eastern

Cypherpunk Technologies EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Cypherpunk Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cypherpunk Technologies Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Cypherpunk Technologies Earnings Headlines

Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.tc pixel
See More Cypherpunk Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cypherpunk Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cypherpunk Technologies and other key companies, straight to your email.

About Cypherpunk Technologies

Cypherpunk Technologies (NASDAQ:CYPH) Inc., previously known as Leap Therapeutics, Inc., is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Cypherpunk is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development.

Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and now trades on the NASDAQ under the ticker CYPH. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.

View Cypherpunk Technologies Profile